>> One would have to think that MediCare/Insurance companies would pull more weight than the doctors, if the cost of deliverying a similar effective drug (i.e., Squalamine) was a lot cheaper.<<
The $340 I referred to is the reimbursement rate for the intravitreal injection --i.e. the procedure. The price for Macugen itself (the drug) has not yet been disclosed.
It is too early to ascertain whether Squalamine will save money for the heathcare system relative to the AMD treatments it will compete against.
Market Data 
Markets 
AI
